Sathornsumetee, S., Rich, J. N., Vredenburgh, J. J., Desjardins, A., Quinn, J. A., Gururangan, S., … Reardon, D. A. (2007). Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 25). AMER SOC CLINICAL ONCOLOGY.

Sathornsumetee, S., J. N. Rich, J. J. Vredenburgh, A. Desjardins, J. A. Quinn, S. Gururangan, M. J. Egorin, A. J. Salvado, H. S. Friedman, and D. A. Reardon. “Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.

Sathornsumetee S, Rich JN, Vredenburgh JJ, Desjardins A, Quinn JA, Gururangan S, et al. Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2007.

Sathornsumetee, S., et al. “Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM).” JOURNAL OF CLINICAL ONCOLOGY, vol. 25, no. 18, AMER SOC CLINICAL ONCOLOGY, 2007.

Sathornsumetee S, Rich JN, Vredenburgh JJ, Desjardins A, Quinn JA, Gururangan S, Egorin MJ, Salvado AJ, Friedman HS, Reardon DA. Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2007.